Dishman Carbogen Amcis Ltd vs Emcure Pharmaceuticals Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 04, 2026

Key Highlights

The Latest Trading Price of Dishman Carbogen Amcis Ltd is ₹ 186.9 as of 04 May 11:10 . The P/E Ratio of Dishman Carbogen Amcis Ltd changed from 161 on March 2022 to 1036 on March 2025 . This represents a CAGR of 59.28% over 4 yearsThe P/E Ratio of Emcure Pharmaceuticals Ltd changed from 29.8 on March 2025 to 29.8 on March 2025 . This represents a CAGR of 0.00% over 1 years The Market Cap of Dishman Carbogen Amcis Ltd changed from ₹ 1708 crore on March 2021 to ₹ 3411 crore on March 2025 . This represents a CAGR of 14.83% over 5 yearsThe Market Cap of Emcure Pharmaceuticals Ltd changed from ₹ 20327 crore on March 2025 to ₹ 20327 crore on March 2025 . This represents a CAGR of 0.00% over 1 years The revenue of Dishman Carbogen Amcis Ltd for the Dec '25 is ₹ 726.46 crore as compare to the Sep '25 revenue of ₹ 660.76 crore. This represent the growth of 9.94% The revenue of Emcure Pharmaceuticals Ltd for the Dec '25 is ₹ 2365 crore as compare to the Sep '25 revenue of ₹ 2272 crore. This represent the growth of 4.06% The ebitda of Dishman Carbogen Amcis Ltd for the Dec '25 is ₹ 119.77 crore as compare to the Sep '25 ebitda of ₹ 157 crore. This represent the decline of -23.71% The ebitda of Emcure Pharmaceuticals Ltd for the Dec '25 is ₹ 456.45 crore as compare to the Sep '25 ebitda of ₹ 478.6 crore. This represent the decline of -4.63% The net profit of Dishman Carbogen Amcis Ltd changed from ₹ -77.57 crore to ₹ -12.97 crore over 7 quarters. This represents a CAGR of -64.01% The net profit of Emcure Pharmaceuticals Ltd changed from ₹ 152.59 crore to ₹ 231.37 crore over 7 quarters. This represents a CAGR of 26.85% The Dividend Payout of Dishman Carbogen Amcis Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Emcure Pharmaceuticals Ltd changed from 4.3 % on March 2021 to 17.92 % on March 2025 . This represents a CAGR of 33.04% over 5 years .

About Dishman Carbogen Amcis Ltd

Dishman Carbogen Amcis Limited was formerly incorporated as 'Carbogen Amcis (India) Limited' on July 17, 2007.
The Company name later on, was changed to 'Dishman Carbogen Amcis Limited' on 27 March 2017.
The Company is engaged in Contract Research and Manufacturing Services (CRAMS) and manufacture and supply of marketable molecules such as specialty chemicals, vitamins & chemicals and disinfectants.
It works manufacturing and research facilities in India, Switzerland, France, The Netherland and China. During the financial year ended 31 March 2017, Dishman Pharmaceuticals and Chemicals Limited (DPCL) and Dishman Care Limited were merged with DPCL's subsidiary Carbogen Amcis (India) Limited, with the key objective of business consolidation and simplification of the Group structure.
The name of Carbogen Amcis (India) Ltd.

About Emcure Pharmaceuticals Ltd

Emcure Pharmaceuticals Limited was originally incorporated as Emcure Pharmaceuticals Private Limited', as a Private Company, pursuant to a Certificate of Incorporation dated April 16, 1981 issued by Registrar of Companies, Maharashtra at Bombay.
Subsequently, Company was converted into a Public Company and the name of Company was changed to Emcure Pharmaceuticals Limited', through a fresh Certificate of Incorporation issued by the RoC, Maharashtra in Pune on September 18, 2001. Emcure Pharmaceuticals an Indian pharmaceutical company engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products across several major therapeutic areas.
In India, they are present across acute and chronic therapeutic areas, and their key therapeutic areas include gynecology, cardiovascular, vitamins, minerals and nutrients, human immunodeficiency virus antivirals, blood-related and oncology/anti-neoplastics.

FAQs for the comparison of Dishman Carbogen Amcis Ltd and Emcure Pharmaceuticals Ltd

Which company has a larger market capitalization, Dishman Carbogen Amcis Ltd or Emcure Pharmaceuticals Ltd?

Market cap of Dishman Carbogen Amcis Ltd is 2,878 Cr while Market cap of Emcure Pharmaceuticals Ltd is 31,850 Cr

What are the key factors driving the stock performance of Dishman Carbogen Amcis Ltd and Emcure Pharmaceuticals Ltd?

The stock performance of Dishman Carbogen Amcis Ltd and Emcure Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Dishman Carbogen Amcis Ltd and Emcure Pharmaceuticals Ltd?

As of May 4, 2026, the Dishman Carbogen Amcis Ltd stock price is INR ₹183.6. On the other hand, Emcure Pharmaceuticals Ltd stock price is INR ₹1679.95.

How do dividend payouts of Dishman Carbogen Amcis Ltd and Emcure Pharmaceuticals Ltd compare?

To compare the dividend payouts of Dishman Carbogen Amcis Ltd and Emcure Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.